Showing 1271-1280 of 1478 results for "".
- Venus Concept Unveils Venus Freeze Plus for Non-Invasive Anti-Aging Treatmentshttps://practicaldermatology.com/news/venus-concept-unveils-venus-freeze-plus-for-non-invasive-anti-aging-treatments/2458432/Venus Concept's non-invasive anti-aging device, Venus Freeze Plus, is now available in the US. It is indicated for the treatment of moderate-to-severe facial wrinkles and rhytides, leading to the tightening of the skin, with no pain or downtime. Venus Freeze Plus works by using Venus
- Kybella for Men May Mean Buh-Bye Beardshttps://practicaldermatology.com/news/kybella-for-men-may-mean-buh-bye-beards/2458456/If Allergan’s double-chin melting injectable Kybella were to really take off among men, we may be seeing a lot fewer beards, jokes bearded Washington DC –based dermatologist Terrence Keaney, MD. Male aesthetics is a growing market,
- It's So Far, So Good for BioPharmX's New Acne Drughttps://practicaldermatology.com/news/its-so-far-so-good-for-biopharmxs-new-acne-drug/2458458/BioPharmX Corporation’s novel topical minocycline, BPX-01, reduced facial P. acnes by more than 90 percent after four weeks, new research shows. In the Phase 2a study, a daily 10 mg dose of topical minocycline offered P. acnes r
- Paratek Initiates Phase 3 Study of Oral Omadacycline for MRSA, Acute Skin Infectionshttps://practicaldermatology.com/news/paratek-initiates-phase-3-study-of-oral-omadacycline-for-mrsa-acute-skin-infections/2458465/The first patient has been dosed in Paratek Pharmaceuticals, Inc.’s second pivotal Phase 3 study of omadacycline for acute bacterial skin and skin structure infections (ABSSSI). Omadacycline is a new once-daily oral and IV, well-tolerated
- Dermatologist Todd Schlesinger to Host Bellafill Discussion Fridayhttps://practicaldermatology.com/news/dermatologist-todd-schlesinger-to-host-bellafill-discussion-friday/2458484/Todd E. Schlesinger, MD, FAAD will host a program on behalf of Suneva, in which he will discuss Suneva's Bellafill® and other products. The event will be held Friday, July 29th, 2016 at 8pm at Towne Stove and Spirits, 900 Boylston Street, Boston. Those interested in atte
- Take That, Acne: BPX-01 Topical Gel Delivers Minocycline Precisely to the Skinhttps://practicaldermatology.com/news/take-that-acne-bpx-01-topical-gel-delivers-minocycline-precisely-to-the-skin/2458490/BioPharmX Corporation’s novel topical minocycline, BPX-01, may be as effective as its oral counterpart minus the systemic side effects, new research suggests. "These results are promising, that topical minocycline gel delivered as BP
- Is 'Mitoiron Claw' the Next Great Sunscreen Ingredient?https://practicaldermatology.com/news/is-mitoiron-claw-the-next-great-sunscreen-ingredient/2458493/A new compound that blocks excess free iron in the mitochondria may offer dramatic protection against Ultraviolet A (UVA) radiation in sunlight, according to scientists at the University of Bath and King's College London. Most sunscreens protect well against solar Ultraviolet B
- CeraVe: Suncare Products Get Skin Cancer Foundation Seal of Recommendationhttps://practicaldermatology.com/news/cerave-suncare-products-get-skin-cancer-foundation-seal-of-recommendation/2458495/Two products from Valeant Consumer Healthcare's CeraVe skincare line have received The Skin Cancer Foundation (SCF) Seal of Recommendation for sunscreens. CeraVe® AM Facial Moisturizing Lotion with SPF 30 has earned the “Daily Use” Seal and CeraVe
- FDA Advisory Arm Recommends Brodalumab For Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-advisory-arm-recommends-brodalumab-for-moderate-to-severe-plaque-psoriasis/2458497/A US. Food and Drug Administration (FDA) advisory panel voted to greenlight Valeant’s IL-17 blocker brodalumab for the treatment of moderate-to-severe plaque psoriasis in adults. The committee voted 18 to 0 in favor of brodalumab injection, 210
- FDA Clears Syneron Candela's UltraShape Power for Fat Destructionhttps://practicaldermatology.com/news/fda-clears-syneron-candelas-ultrashape-power-for-fat-destruction/2458499/The FDA cleared Syneron Medical Ltd.'s non-invasive fat destruction device, UltraShape Power. for non-invasive reduction of abdominal circumference via fat cell destruction. UltraShape Power uses focused, pulsed mechanical ultrasound energy to target and destroy fat, offering measurab